Showing results (81-90 of 167) with videos related to

Sort By:
Pageof 17
Pharmaceuticals (Basel, Switzerland)|August 26, 2022
Gastroesophageal Reflux Disease in Idiopathic Pulmonary Fibrosis: Viewer or Actor? To Treat or Not to Treat?Barbara Ruaro, Riccardo Pozzan, Paola Confalonieri, et al.
Journal of Clinical Medicine|February 9, 2020
Nintedanib Treatment for Idiopathic Pulmonary Fibrosis Patients Who Have Been Switched from Pirfenidone Therapy: A Retrospective Case Series StudyAndrea Vianello, Francesco Salton, Beatrice Molena, et al.
Diagnostics (Basel, Switzerland)|November 27, 2021
High-Resolution Computed Tomography: Lights and Shadows in Improving Care for SSc-ILD PatientsBarbara Ruaro, Elisa Baratella, Paola Confalonieri, et al.
Orphanet Journal of Rare Diseases|March 6, 2019
Is early detection of late-onset Pompe disease a pneumologist's affair? A lesson from an Italian screening studyMarco Confalonieri, Michele Vitacca, Raffaele Scala, et al.
Pharmaceuticals (Basel, Switzerland)|February 26, 2025
Assessment of Treatment Effects of Aminaphtone by Capillaroscopy in a Patient with Raynaud's PhenomenonGianluca Screm, Lucrezia Mondini, Francesco Salton, et al.
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|December 10, 2024
Autoantibodies in sarcoidosis: Innocent bystander or promising biomarker for organ involvement?Riccardo Pozzan, Francesco Salton, Paola Confalonieri, et al.
Diagnostics (Basel, Switzerland)|December 24, 2021
High-Resolution Computed Tomography and Lung Ultrasound in Patients with Systemic Sclerosis: Which One to Choose?Barbara Ruaro, Elisa Baratella, Paola Confalonieri, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 3, 2016
Epithelial to mesenchymal transition-related proteins ZEB1, β-catenin, and β-tubulin-III in idiopathic pulmonary fibrosisMarco Chilosi, Anna Caliò, Andrea Rossi, et al.
Plos One|February 16, 2017
Keratin14 mRNA expression in human pneumocytes during quiescence, repair and diseaseMarco Confalonieri, Emanuele Buratti, Gabriele Grassi, et al.
Pharmaceuticals (Basel, Switzerland)|June 1, 2023
Nintedanib in Idiopathic Pulmonary Fibrosis: Tolerability and Safety in a Real Life Experience in a Single Centre in Patients also Treated with Oral Anticoagulant TherapyBarbara Ruaro, Ilaria Gandin, Riccardo Pozzan, et al.
Pageof 17